← Leaderboards
James B Caress
Wake Forest University
$367,327
Attributed
$367,327
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $98.1K · FY2005–10$100K$75K$50K$25K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$367,327 · 20
By mechanism
M01$367,327 · 20
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University
Same institution · by research overlap
- Francis O Walker$211,840
- Daniel B Kim-Shapiro$10,363,938
- James C Eisenach$18,874,166
- Peter Donofrio$0
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseInstitutionSourceUnited States National Institutes Of HealthFundingResourcesGrantEnrollmentPharmaceutical PreparationsClinical TrialsClinical ResearchAmyotrophic Lateral SclerosisParticipantOutcome MeasureSafetyPlacebosSiteRandomizedHereditary DiseaseIn VitroCeftriaxoneBaseDaughter
Grant awards (23)
CLINICAL TRIAL: CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS$40,964
M01 · FY2010 · RR · contact PI
CHANGES IN NEUROMUSCULAR JUNCTIONS IN ALS$16,732
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$14,423
M01 · FY2010 · RR · contact PI
A MULTICENTER STUDY FOR THE VALIDATION OF ALS BIOMARKERS$12,116
M01 · FY2010 · RR · contact PI
ELECTRICAL IMPEDANCE MYOGRAPHY IN ALS$12,116
M01 · FY2010 · RR · contact PI
CHANGES IN NEUROMUSCULAR JUNCTIONS IN ALS$1,731
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$16,060
M01 · FY2009 · RR · contact PI
ELECTRICAL IMPEDANCE MYOGRAPHY IN ALS$13,140
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS$8,274
M01 · FY2009 · RR · contact PI
A MULTICENTER STUDY FOR THE VALIDATION OF ALS BIOMARKERS$3,894
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS$45,936
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$20,645
M01 · FY2008 · RR · contact PI
A MULTI-CENTER STUDY OF MINOCYCLINE IN ALS$21,196
M01 · FY2007 · RR · contact PI
PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$15,012
M01 · FY2007 · RR · contact PI
CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS$9,714
M01 · FY2007 · RR · contact PI
A MULTI-CENTER STUDY OF MINOCYCLINE IN ALS$35,495
M01 · FY2006 · RR · contact PI
PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$16,382
M01 · FY2006 · RR · contact PI
A MULTI-CENTER STUDY OF MINOCYCLINE IN ALS$28,346
M01 · FY2005 · RR
PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$19,461
M01 · FY2005 · RR
Pilot Huntington at Risk Observational Study (PHAROS)$13,865
M01 · FY2004 · RR
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis$1,825
M01 · FY2004 · RR
PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$0
M01 · FY2002 · RR
PILOT HUNTINGTON AT RISK OBSERVATIONAL STUDY (PHAROS)$0
M01 · FY2000 · RR